Back to Search
Start Over
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group
- Source :
- Cytometry Part B-clinical Cytometry, 104(1), 77-86. Wiley-Liss Inc., van de Loosdrecht, A A, Kern, W, Porwit, A, Valent, P, Kordasti, S, Cremers, E, Alhan, C, Duetz, C, Dunlop, A, Hobo, W, Preijers, F, Wagner-Ballon, O, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenschink-Brodersen, L, Font, P, Johansson, U, Loken, M R, te Marvelde, J G, Matarraz, S, Ogata, K, Oelschlaegel, U, Orfao, A, Psarra, K, Subirá, D, Wells, D A, Béné, M C, Della Porta, M G, Burbury, K, Bellos, F, van der Velden, V H J, Westers, T M, Saft, L & Ireland, R 2023, ' Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome : A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group ', Cytometry Part B-Clinical Cytometry, vol. 104, no. 1, pp. 77-86 . https://doi.org/10.1002/cyto.b.22044, Cytometry. Part B-Clinical Cytometry, 104, 77-86, Cytometry Part B: Clinical Cytometry, Cytometry Part B: Clinical Cytometry, 2021, Online ahead of print. ⟨10.1002/cyto.b.22044⟩, Cytometry Part B-Clinical Cytometry, 104(1), 77-86. Wiley-Liss Inc., Cytometry. Part B-Clinical Cytometry, 104, 1, pp. 77-86
- Publication Year :
- 2023
-
Abstract
- Contains fulltext : 290800.pdf (Publisher’s version ) (Open Access) This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients. 01 januari 2023
- Subjects :
- standardization
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
flow cytometry
CONSORTIUM
[SDV.CAN]Life Sciences [q-bio]/Cancer
PROGNOSTIC SCORING SYSTEM
DIAGNOSIS
CYTOGENETICS
myelodysplastic syndromes
CLASSIFICATION
VALIDATION
All institutes and research themes of the Radboud University Medical Center
[SDV.CAN] Life Sciences [q-bio]/Cancer
consensus
hemic and lymphatic diseases
CELLS
SUBGROUPS
ELN
CYTOMORPHOLOGY
Subjects
Details
- Language :
- English
- ISSN :
- 15524949 and 15524957
- Database :
- OpenAIRE
- Journal :
- Cytometry Part B-clinical Cytometry, 104(1), 77-86. Wiley-Liss Inc., van de Loosdrecht, A A, Kern, W, Porwit, A, Valent, P, Kordasti, S, Cremers, E, Alhan, C, Duetz, C, Dunlop, A, Hobo, W, Preijers, F, Wagner-Ballon, O, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenschink-Brodersen, L, Font, P, Johansson, U, Loken, M R, te Marvelde, J G, Matarraz, S, Ogata, K, Oelschlaegel, U, Orfao, A, Psarra, K, Subirá, D, Wells, D A, Béné, M C, Della Porta, M G, Burbury, K, Bellos, F, van der Velden, V H J, Westers, T M, Saft, L & Ireland, R 2023, ' Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome : A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group ', Cytometry Part B-Clinical Cytometry, vol. 104, no. 1, pp. 77-86 . https://doi.org/10.1002/cyto.b.22044, Cytometry. Part B-Clinical Cytometry, 104, 77-86, Cytometry Part B: Clinical Cytometry, Cytometry Part B: Clinical Cytometry, 2021, Online ahead of print. ⟨10.1002/cyto.b.22044⟩, Cytometry Part B-Clinical Cytometry, 104(1), 77-86. Wiley-Liss Inc., Cytometry. Part B-Clinical Cytometry, 104, 1, pp. 77-86
- Accession number :
- edsair.pmid.dedup....d910b23f01c8268d10fa96896c2a71e7